
Mettler Toledo
MTD · NYSE · Life Sciences Tools & Services
Quotes delayed up to 15 min. Updated 16 Nov, 16:00 New York time
- Market cap
- $34,1 bn
- Div. yield
- —
- Year to date
- +24,7%
Ratio score
based on 8 metrics as of 16.11.2026 ·
Verdict by our methodology based on current metrics. Not an investment recommendation.
Key metrics
3 ✓ · 4 — · 1 ✕ · 2 n/a · hover over a row or tap it to see the trend
All metrics
| Metric | Value | 5-year median | Industry median |
|---|---|---|---|
| P/E TTM | 36,5 | 32,3 | 37,9 |
| Forward P/E | 35,9 | — | 29,5 |
| PEG | 2,5 | — | 3,7 |
| P/S | 8,1 | 7,0 | 6,6 |
| EV/EBITDA | 29,9 | 26,6 | 29,9 |
| P/FCF | 39,2 | — | 38,7 |
| P/B | 439,2 | 74,9 | 5,4 |
Industry median — across 11 profitable companies in “Life Sciences Tools & Services” in Ratio. Revenue and EPS forecasts for future years and the number of employees are in the paid data plan.
Price chart
Compare with
Choose a stock
Closing prices adjusted for splits and dividends. The S&P 500 index and the intraday chart come later.
Analysts
Ratings, 19 analysts
- Buy
- 9
- Hold
- 9
- Sell
- 1
Beat the EPS forecast in 4 of the last 4 quarters
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| Q3 2026 | 12,22 | 12,57 | Up +2,9% |
| Q2 2026 | 10,90 | 11,46 | Up +5,2% |
| Q1 2026 | 8,79 | 8,91 | Up +1,4% |
| Q4 2025 | 12,93 | 13,36 | Up +3,3% |
Price targets and yearly revenue and EPS forecasts are in the paid data plan. These are analysts' opinions, not our verdict.
Financials in charts
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,09 bn | 1,03 bn | 947 m | 1,13 bn | 1,03 bn | 983 m | 884 m | 1,05 bn | 955 m | 947 m | 926 m | 935 m |
| EPS | 12,29 | 11,55 | 8,33 | 13,93 | 10,57 | 9,76 | 7,81 | 11,93 | 9,96 | 10,37 | 8,24 | 8,53 |
| Margin | 22,5% | 22,7% | 17,9% | 25,3% | 21,1% | 20,6% | 18,5% | 24,1% | 22,2% | 23,4% | 19,2% | 19,8% |
| FCF | 281 m | 283 m | 122 m | 184 m | 275 m | 212 m | 177 m | 225 m | 233 m | 234 m | 173 m | 249 m |
From SEC reports. TTM is the sum of 4 quarters; a year is TTM at the end of the calendar year. Forecast bars are in the paid data plan.
Owners
Ownership structure and major holders (13F filings) are in the paid data plan. They are not part of the score or the traffic light.
Insider trades over 12 months
Over 12 months: no purchases, sales $20,3 m.
| Name | Amount | Shares | Price |
|---|---|---|---|
| keller gerry9 Nov 2026 · sale | $43 472 | 25 | $1 738,88 |
| keller gerry9 Nov 2026 · sale | $710 842 | 410 | $1 733,76 |
| kaltenbach patrick27 Aug 2026 · sale | $1,34 m | 942 | $1 425,00 |
| salice thomas p5 Aug 2026 · sale | $600 651 | 417 | $1 440,41 |
| salice thomas p3 Aug 2026 · sale | $599 517 | 415 | $1 444,62 |
| keller gerry3 Aug 2026 · sale | $342 514 | 240 | $1 427,14 |
| vadala shawn3 Aug 2026 · sale | $3,21 m | 2 240 | $1 432,00 |
| vadala shawn10 Feb 2026 · sale | $1,13 m | 800 | $1 410,12 |
| de la guerroniere marc25 Nov 2025 · sale | $3,71 m | 2 475 | $1 500,00 |
| de la guerroniere marc25 Nov 2025 · sale | $5,30 m | 3 580 | $1 480,00 |
| vadala shawn25 Nov 2025 · sale | $1,51 m | 1 000 | $1 511,00 |
| vadala shawn24 Nov 2025 · sale | $1,49 m | 1 025 | $1 452,00 |
| keller gerry21 Nov 2025 · sale | $334 785 | 236 | $1 418,58 |
SEC Form 4. Titles and trading plans are not in the data. They are not part of the score or the traffic light.
About the company
- Industry
- Life Sciences Tools & Services
- Exchange
- NYSE
- Country
- US
- IPO date
- 14 Nov 1997
- Website
- www.mt.com
Company description, revenue by segment and region, and the CEO will come later.
Earnings
- Next report
- date not announced
An AI summary of the earnings call will come later.
Peers
| Company | Price | ||||
|---|---|---|---|---|---|
ILMNIllumina, Inc. | $198,00 | 75★★★★★★★★★would consider | 33,6 | +5,8% | 19,7% |
WSTWest Pharmaceutical Services | $417,80 | 83★★★★★★★★★would consider | 45,5 | +12,6% | 18,8% |
IQVIQVIA | $264,73 | 72★★★★★★★★★would consider | 31,3 | +8,8% | 8,1% |
WATWaters Corporation | $453,42 | 29★★★★★★★would not consider | 269,0 | — | 1,8% |
AAgilent Technologies | $172,92 | 78★★★★★★★★★would consider | 34,1 | +8,6% | 19,5% |
Ratio — a score by our methodology, not an investment recommendation.




